Tag results:

monocytes

Pan-Protective Anti-alphavirus Human Antibodies Target a Conserved E1 Protein Epitope

[Cell] Scientists identified DC2.112 and DC2.315, two pan-protective yet poorly neutralizing human monoclonal antibodies that avidly bind to viral antigen on the surface of cells infected with arthritogenic and encephalitic alphaviruses.

Melatonin as an Immunomodulator in Children with Down Syndrome

[Pediatric Research] Scientists demonstrated that melatonin had several significant effects by reducing CD11b and TLR4 expression, attenuating TLR signaling, genes involved in the inflammasome and had the potential to reduce LPS-induced inflammatory responses.

Hematopoietic Upstream Stimulating Factor 1 Deficiency Is Associated with Increased Atherosclerosis Susceptibility in LDL Receptor Knockout Mice

[Scientific Reports] Scientists tested whether selective hematopoietic upstream stimulatory factor 1 (USF1) deficiency could also beneficially impact the development of atherosclerosis. Absence of USF1 function in bone marrow-derived cells was associated with exacerbated blood leukocyte and peritoneal leukocyte lipid loading and an increased atherosclerosis susceptibility.

Targeting of IL-10R on Acute Myeloid Leukemia Blasts with Chimeric Antigen Receptor-Expressing T Cells

[Blood Cancer Journal] The authors found that interleukin-10 receptor (IL-10R) was overexpressed in most acute myeloid luekemia cells, and played an important role in promoting the stemness of leukemia cells.

Metformin Inhibits Cholesterol-Induced Adhesion Molecule Expression via Activating the AMPK Signaling Pathway in Vascular Smooth Muscle Cells

[Molecular Medicine Reports] Human vascular smooth muscle cells were loaded with cholesterol and different concentrations of metformin. The expression levels of adhesion molecules were assessed via reverse transcription‑quantitative PCR and western blotting.

Immunomodulation by Durvalumab and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma

[Scientific Reports] Scientists sought to understand how the programmed death ligand 1 inhibitor durvalumab and the immunomodulatory agent pomalidomide regulate immune cell activation and function in patients with relapsed/refractory multiple myeloma.

Popular